13FGuru
Sign in with Google Sign in with Discord

NYSE · Technology

VEEVA SYS INC VEEV

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands.

Sources StockAnalysis company profile stockanalysis.com
Computer Software: Prepackaged Software

Company profile

Business mix

  • The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies.
  • It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data.
  • In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials.
  • Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within health information services?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 30.61 FCF 5.85% Buyback -0.75%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baillie Gifford legacy James Anderson 0.1% $129.1M 2026-03-31

Recent trading changes over the last 1 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 1 13F filing periods
Net reducers 4 Last 1 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $129.1M Estimated from net added shares
Reduction amount $1.1B Estimated from net reduced shares
Net share change / base shares -81.7% -4,034,306 / 4,937,413
Tiger Global Management Chase Coleman 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Sold out Shares -100.0% 13F value change -$540.3M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 2,420,500 Last 1 periods -2,420,500 (-100.0%) Total shares 0 Value $0
Baron Capital Ron Baron 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -35.8% 13F value change -$29.0M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 262,070 Last 1 periods -93,944 (-35.8%) Total shares 168,126 Value $29.5M
Durable Capital Partners Henry Ellenbogen 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Sold out Shares -100.0% 13F value change -$212.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 951,896 Last 1 periods -951,896 (-100.0%) Total shares 0 Value $0
Stockbridge Partners 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Sold out Shares -100.0% 13F value change -$290.8M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 1,302,898 Last 1 periods -1,302,898 (-100.0%) Total shares 0 Value $0
Baillie Gifford legacy James Anderson 1 filing periods
13F 2026-03-31 Filed 2026-05-08
Major increase Shares 1499861.2% 13F value change +$129.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 49 Last 1 periods +734,932 (+1499861.2%) Total shares 734,981 Value $129.1M

Recent mentions

No public mentions.